Ebola virus (EBOV), a member of the filovirus group, causes severe hemorrhagic fever in humans. The Innate immune response is an important target for EBOV, and Dr. Basler's group has identified filovirus proteins that inhibit interferon-a/p (IFN a/p) production. EBOV VP35 (eVP35) and MARV VP35 (mVP35) impair IFN a/p production by targeting RIG-l-like receptor signaling pathways. In fact, EBOVs with impaired VP35 IFN-antagonism are attenuated in mice and guinea pigs indicating that VP35 inhibitors can be used to treat EBOV infection. Dr. Basler's and Dr. Amarasinghe's groups have also shown that EBOV VP24 (eVP24) and MARV VP40 (mVP40) proteins inhibit Jak-STAT signaling triggered by IFN a/p and IFND, thereby blocking the antiviral effects of IFNs. We hypothesize that small molecules targeting these filoviral proteins can be identified and developed into therapeutic and prophylactic agents that are useful for combating filovirus biothreats. They can be used alone to augment the production of IFNs during infection or synergistically in combination with therapeutically-administered IFNs or possibly with other therapeutic agents. This multi-project Center builds on these exciting findings and new assay development studies (Project 1) to identify inhibitors of eVP35, mVP35, eVP24 and mVP40. In Project 2, Microbiofix will adapt the assays to HTS format and conduct screening, confirmation, validation, and selectivity/cytotoxicity assays, and In conjunction with Dr. Ready's group at UT Southwestern, medicinal chemistry optimization, and toxicity/PK/PD studies. The screening campaign will apply 4 HTS assays (eVP35, mVP35, eVP24 and mVP40) to the Microbiofix (200,000 compounds) and ICCB-L (300,000 compounds) screening libraries to identify compounds that act as IFN agonists. Project 1 will characterize the biochemical, structural and mechanistic basis of inhibition by leads and optimized leads. The infectious core will evaluate the hit and lead compounds against infectious filoviruses In vitro and in vivo. Resulting small molecule Inhibitors may be developed to generate new therapeutic agents to enhance patient outcome in Infection as well as chemical tools to study the role of these filoviral proteins.

Public Health Relevance

Ebola virus causes highly lethal viral hemorrhagic fever syndrome and has been classified as a Category A bioweapons agents by the Centers for Disease Control and Prevention (CDC). There are no effective vaccines or antiviral against Ebola virus Infection In humans. The overall goal of this project is to discover and develop small molecule therapeutic agents against Ebola virus to respond to natural outbreaks of Ebola virus infection and to counter potential acts of bioterrorism.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
1U19AI109664-01
Application #
8642739
Study Section
Special Emphasis Panel (ZAI1-LR-M (J1))
Project Start
Project End
Budget Start
2014-03-01
Budget End
2015-02-28
Support Year
1
Fiscal Year
2014
Total Cost
$1,212,185
Indirect Cost
$146,105
Name
Icahn School of Medicine at Mount Sinai
Department
Type
DUNS #
078861598
City
New York
State
NY
Country
United States
Zip Code
10029
Esposito, Anthony M; Cheung, Pamela; Swartz, Talia H et al. (2016) A high throughput Cre-lox activated viral membrane fusion assay identifies pharmacological inhibitors of HIV entry. Virology 490:6-16
Pleet, Michelle L; Mathiesen, Allison; DeMarino, Catherine et al. (2016) Ebola VP40 in Exosomes Can Cause Immune Cell Dysfunction. Front Microbiol 7:1765
Leung, Daisy W; Amarasinghe, Gaya K (2016) When your cap matters: structural insights into self vs non-self recognition of 5' RNA by immunomodulatory host proteins. Curr Opin Struct Biol 36:133-41
Baer, Alan; Shafagati, Nazly; Benedict, Ashwini et al. (2016) Protein Phosphatase-1 regulates Rift Valley fever virus replication. Antiviral Res 127:79-89
Edwards, Megan R; Liu, Gai; Mire, Chad E et al. (2016) Differential Regulation of Interferon Responses by Ebola and Marburg Virus VP35 Proteins. Cell Rep 14:1632-40
Rialdi, Alex; Campisi, Laura; Zhao, Nan et al. (2016) Topoisomerase 1 inhibition suppresses inflammatory genes and protects from death by inflammation. Science 352:aad7993
Chatterjee, Srirupa; Basler, Christopher F; Amarasinghe, Gaya K et al. (2016) Molecular Mechanisms of Innate Immune Inhibition by Non-Segmented Negative-Sense RNA Viruses. J Mol Biol 428:3467-82
Basler, Christopher F (2015) Innate immune evasion by filoviruses. Virology 479-480:122-30
Messaoudi, Ilhem; Basler, Christopher F (2015) Immunological features underlying viral hemorrhagic fevers. Curr Opin Immunol 36:38-46
Edwards, Megan R; Pietzsch, Colette; Vausselin, Thibaut et al. (2015) High-Throughput Minigenome System for Identifying Small-Molecule Inhibitors of Ebola Virus Replication. ACS Infect Dis 1:380-7

Showing the most recent 10 out of 30 publications